NCT04925167

Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO

Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO: A Randomized Controlled Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Beijing Chao Yang Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Unfractionated heparin is most common in the anticoagulation management of V-V ECMO. However, many side effects of unfractionated heparin, such as HIT, antithrombin deficiency, etc seriously affects the prognosis of patients. Argatroban is kind of direct thrombin inhibitors, which could be used used as an alternative anticoagulant of unfractionated heparin when HIT or antithrombin deficiency, etc. At present, there is no power enough evidence for the application of argatroban in V-V ECMO. This study aims to evaluat the safety and effectiveness of argatroban in the anticoagulation management of V-V ECMO compared with unfractionated heparin.

Conditions

• Respiratory Failure

Interventions

Type	Name	Description
DRUG	Argatroban	Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.
DRUG	unfractionated heparin	unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.

Timeline

• Start date: 2021-07-06
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2021-06-14
• Last updated: 2024-03-26

Locations

1 site across 1 country: China